Regeneron Pharmaceuticals: Hypercholesterolemia trials

The registry lists 20 Hypercholesterolemia studies with Regeneron Pharmaceuticals as lead sponsor. 0 are open to participants now and 17 have results posted.

Phase 1 1Phase 2 6Phase 3 10Phase 4 2No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial HypercholesterolemiaCompletedNCT04233918Phase 3Results posted
• Long Term Safety Study of PRALUENTTerminatedNCT03694197Phase 4Results posted
• Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial HypercholesterolemiaCompletedNCT03409744Phase 3Results posted
• Efficacy and Safety of Evinacumab in Patients With Homozygous Familial HypercholesterolemiaCompletedNCT03399786Phase 3Results posted
• Study of Evinacumab (REGN1500) in Participants With Persistent HypercholesterolemiaCompletedNCT03175367Phase 2Results posted
• Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)CompletedNCT03156621Phase 3Results posted
• Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to PlaceboCompletedNCT02957682Phase 4Results posted
• Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis TherapyCompletedNCT02326220Phase 3Results posted
• Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)CompletedNCT02265952Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)CompletedNCT01926782Phase 3Results posted
• Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)CompletedNCT01730053Phase 3Results posted
• Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)CompletedNCT01730040Phase 3Results posted
• Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)CompletedNCT01709513Phase 3Results posted
• Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)CompletedNCT01709500Phase 3Results posted
• A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B GeneCompletedNCT01604824Phase 2Results posted
• Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)CompletedNCT01576484Phase 2Results posted
• Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH HypercholesterolemiaCompletedNCT01266876Phase 2Results posted
• A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have HypercholesterolemiaActive, not recruitingNCT07477704Phase 2
• Praluent® (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance StudyTerminatedNCT03379558
• Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant AtorvastatinCompletedNCT01161082Phase 1